Advertisement

Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression

  • Davide Festi
  • Francesca Lodato
  • Giuseppe Mazzella
  • Antonio Colecchia

Keywords

Liver Transplantation Chronic Hepatitis Sustained Virological Response Acute Rejection Cirrhotic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdelmalek, M.F., Firpi, R.J., Soldevila-Pico, C., Reed, A.I., Hemming, A.W., Liu, C., Crawford, J.M., Davis, G.L., Nelson, D.R. (2004). Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation, 10: 199–207.PubMedGoogle Scholar
  2. Adam, R., McMaster, P., O’Grady, J.G., Castaing, D., Klempnauer, J.L., Jamieson, N., Neuhaus, P., Lerut, J., Salizzoni, M., Pollard, S., Muhlbacher, F., Rogiers, X., Garcia Valdecasas, J.C., Berenguer, J., Jaeck, D., Moreno Gonzalez, E. (2003). Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transplantation, 9: 1231–1243.PubMedGoogle Scholar
  3. Afdhal, N., Freilich, B., Levine, R., Black, M., Brown, R., Jr., Mansour, H., O’Brien, M., Brass, C. (2004). Colchicine versus PEG-Interferon long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology, 40: 239A.Google Scholar
  4. Ahmad, J., Dodson, S.F., Demetris, A.J., Fung, J.J., Shakil, A.O. (2001). Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alpha alone versus interferon alpha and ribavirin. Liver Transplantation, 7: 863–869.PubMedGoogle Scholar
  5. Alberti, A.B., Belli, L.S., Airoldi, A., de Carlis, L., Rondinara, G., Minola, E., Vangeli, M., Cernuschi, A., D’Amico, M., Forti, D., Pinzello, G. (2001). Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transplantation, 7: 870–876.PubMedGoogle Scholar
  6. Armstrong, G.L., Alter, M.J., McQuillan, G.M., Margolis, H.S. (2000). The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology, 31: 777–782.PubMedGoogle Scholar
  7. Azzaroli, F., Accogli, E., Nigro, G., Trere, D., Giovanelli, S., Miracolo, A., Lodato, F., Montagnani, M., Tame, M., Colecchia, A., Mwangemi, C., Festi, D., Roda, E., Derenzini, M., Mazzella, G. (2004). Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World Journal of Gastroenterology, 10: 3099–3102.PubMedGoogle Scholar
  8. Benvegnu, L., Chemello, L., Noventa, F., Fattovich, G., Pontisso, P., Alberti, A. (1998). Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer, 83: 901–909.PubMedGoogle Scholar
  9. Berardi, S., Lodato, F., Gramenzi, A., D’Errico, A., Lenzi, M., Bontadini, A., Morelli, M.C., Tame, M.R., Piscaglia, F., Biselli, M., Sama, C., Mazzella, G., Pinna, A.D., Grazi, G.L., Bernardi, M., Andreone, P. (2006). High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut. Jun 23 [Epub ahead of print].Google Scholar
  10. Berenguer, M. (2003). Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplantation, 9: S44–47.PubMedGoogle Scholar
  11. Berenguer, M., Ferrell, L., Watson, J., Prieto, M., Kim, M., Rayon, M., Cordoba, J., Herola, A., Ascher, N., Mir, J., Berenguer, J., Wright, T.L. (2000). HCV-related fibrosis progression following liver transplantation: increase in recent years. Journal of Hepatology, 32: 673–684.PubMedGoogle Scholar
  12. Berenguer, M., Lopez-Labrador, F.X., Wright, T.L. (2001). Hepatitis C and liver transplantation. Journal of Hepatology, 35: 666–678.PubMedGoogle Scholar
  13. Berenguer, M., Palau, A., Fernandez, A., Benlloch, S., Aguilera, V., Prieto, M., Rayon, J.M., Berenguer, J. (2006). Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplantation, 12: 1067–1076.PubMedGoogle Scholar
  14. Berenguer, M., Prieto, M., Cordoba, J., Rayon, J.M., Carrasco, D., Olaso, V., San-Juan, F., Gobernado, M., Mir, J., Berenguer, J. (1998). Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. Journal of Hepatology, 28: 756–763.PubMedGoogle Scholar
  15. Bizollon, T., Ahmed, S.N., Radenne, S., Chevallier, M., Chevallier, P., Parvaz, P., Guichard, S., Ducerf, C., Baulieux, J., Zoulim, F., Trepo, C. (2003). Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut, 52: 283–287.PubMedGoogle Scholar
  16. Bizollon, T., Pradat, P., Mabrut, J.Y., Chevallier, M., Adham, M., Radenne, S., Souquet, J.C., Ducerf, C., Baulieux, J., Zoulim, F., Trepo, C. (2005). Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. American Journal of Transplantation, 5: 1909–1913.PubMedGoogle Scholar
  17. Brillanti, S., Vivarelli, M., De Ruvo, N., Aden, A.A., Camaggi, V., D’Errico, A., Furlini, G., Bellusci, R., Roda, E., Cavallari, A. (2002). Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transplantation, 8: 884–888.PubMedGoogle Scholar
  18. Bruno, S., Silini, E., Crosignani, A., Borzio, F., Leandro, G., Bono, F., Asti, M., Rossi, S., Larghi, A., Cerino, A., Podda, M., Mondelli, M.U. (1997). Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology, 25: 754–758.PubMedGoogle Scholar
  19. Burak, K.W., Kremers, W.K., Batts, K.P., Wiesner, R.H., Rosen, C.B., Razonable, R.R., Paya, C.V., Charlton, M.R. (2002). Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transplantation, 8: 362–369.PubMedGoogle Scholar
  20. Burra, P., Targhetta, S., Pevere, S., Boninsegna, S., Guido, M., Canova, D., Brolese, A., Masier, A., D’Aloiso, C., Germani, G., Tomat, S., Fagiuoli, S. (2006). Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Transplantation Proceedings, 38: 1127–1130.PubMedGoogle Scholar
  21. Camma, C., Giunta, M., Andreone, P., Craxi, A. (2001). Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. Journal of Hepatology, 34: 593–602.PubMedGoogle Scholar
  22. Castells, L., Vargas, V., Allende, H., Bilbao, I., Luis Lazaro, J., Margarit, C., Esteban, R., Guardia, J. (2005). Combined treatment with PEGylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. Journal of Hepatology, 43: 53–59.PubMedGoogle Scholar
  23. Chalasani, N., Manzarbeitia, C., Ferenci, P., Vogel, W., Fontana, R.J., Voigt, M., Riely, C., Martin, P., Teperman, L., Jiao, J., Lopez-Talavera, J.C. (2005). PEGinterferon alpha-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology, 41: 289–298.PubMedGoogle Scholar
  24. Chiaramonte, M., Stroffolini, T., Vian, A., Stazi, M.A., Floreani, A., Lorenzoni, U., Lobello, S., Farinati, F., Naccarato, R. (1999). Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer, 85: 2132–2137.PubMedGoogle Scholar
  25. Colombo, M., de Franchis, R., Del Ninno, E., Sangiovanni, A., De Fazio, C., Tommasini, M., Donato, M.F., Piva, A., Di Carlo, V., Dioguardi, N. (1991). Hepatocellular carcinoma in Italian patients with cirrhosis. New England Journal of Medicine, 325: 675–680.PubMedGoogle Scholar
  26. Cotler, S.J., Ganger, D.R., Kaur, S., Rosenblate, H., Jakate, S., Sullivan, D.G., Ng, K.W., Gretch, D.R., Jensen, D.M. (2001). Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation, 71: 261–266.PubMedGoogle Scholar
  27. Crippin, J.S., McCashland, T., Terrault, N., Sheiner, P., Charlton, M.R. (2002). A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation, 8: 350–355.PubMedGoogle Scholar
  28. Czaja, A.J. (2002). Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transplantation, 8: 505–513.PubMedGoogle Scholar
  29. Davis, G.L., Albright, J.E., Cook, S.F., Rosenberg, D.M. (2003). Projecting future complications of chronic hepatitis C in the United States. Liver Transplantation, 9: 331–338.PubMedGoogle Scholar
  30. De Ruvo, N., Cucchetti, A., Lauro, A., Masetti, M., Cautero, N., Di Benedetto, F., Dazzi, A., Del Gaudio, M., Ravaioli, M., Zanello, M., La Barba, G., di Francesco, F., Risaliti, A., Ramacciato, G., Pinna, A.D. (2005). Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation Proceedings, 37: 2607–2608.PubMedGoogle Scholar
  31. Degos, F., Christidis, C., Ganne-Carrie, N., Farmachidi, J.P., Degott, C., Guettier, C., Trinchet, J.C., Beaugrand, M., Chevret, S. (2000). Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut, 47: 131–136.PubMedGoogle Scholar
  32. Di Bisceglie, A.M., Hoofnagle, J.H. (2002). Optimal therapy of hepatitis C. Hepatology, 36 (5 Suppl. 1): S121–127.PubMedGoogle Scholar
  33. Dousset, B., Conti, F., Houssin, D., Calmus, Y. (1994). Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. New England Journal of Medicine, 330: 1160–1161.PubMedGoogle Scholar
  34. Dumortier, J., Scoazec, J.Y., Chevallier, P., Boillot, O. (2004). Treatment of recurrent hepatitis C after liver transplantation: a pilot study of PEGinterferon alpha-2b and ribavirin combination. Journal of Hepatology, 40: 669–674.PubMedGoogle Scholar
  35. Durelli, L., Ferrero, B., Oggero, A., Verdun, E., Ghezzi, A., Montanari, E., Zaffaroni, M. (2001). Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. Journal of Clinical Endocrinology & Metabolism, 86: 3525–3532.Google Scholar
  36. Eason, J.D., Nair, S., Cohen, A.J., Blazek, J.L., Loss, G.E., Jr. (2003). Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation, 75: 1396–1399.PubMedGoogle Scholar
  37. El-Serag, H.B. (2001). Epidemiology of hepatocellular carcinoma. Clinical Liver Disease, 5: 87–107, vi.Google Scholar
  38. Everson, G.T. (2005). Treatment of hepatitis C in the patient with decompensated cirrhosis. Clinical Gastroenterology and Hepatology, 3 (10 Suppl. 2): S106–112.PubMedGoogle Scholar
  39. Everson, G.T., Heathcote, J., Pappas, S.C. (2004a). Histologic benefit of Peg-Interferon alpha 2a (40 KD) (PEGASYS) monotherapy in patients with advanced fibrosis or cirrhosis due to chronic hepatitis C. Hepatology, 40: 316A.Google Scholar
  40. Everson, G.T., Hoefs, J.C., Malet, P. (2004b). Impaired virologic response in patients with advanced liver disease due to chronic hepatitis C is independently linked to severity of disease: results from the HALT C trial. Hepatology, 40: 180A.Google Scholar
  41. Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J.T., Thomas, H., Njapoum, C., Casarin, C., Bonetti, P., Fuschi, P., Basho, J., Tocco, A., Bhalla, A., Galassini, R., Noventa, F., Schalm, S.W., Realdi, G. (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 112: 463–472.PubMedGoogle Scholar
  42. Fattovich, G., Giustina, G., Favarato, S., Ruol, A. (1996). A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. Journal of Hepatology, 24: 38–47.PubMedGoogle Scholar
  43. Fattovich, G., Pantalena, M., Zagni, I., Realdi, G., Schalm, S.W., Christensen, E. (2002). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology, 97: 2886–2895.PubMedGoogle Scholar
  44. Fattovich, G., Stroffolini, T., Zagni, I., Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127 (5 Suppl. 1): S35–50.PubMedGoogle Scholar
  45. Feray, C., Samuel, D., Gigou, M., Paradis, V., David, M.F., Lemonnier, C., Reynes, M., Bismuth, H. (1995). An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology, 22 (4 Pt. 1): 1084–1089.PubMedGoogle Scholar
  46. Forman, L.M., Lewis, J.D., Berlin, J.A., Feldman, H.I., Lucey, M.R. (2002). The association between hepatitis C infection and survival after orthotropic liver transplantation. Gastroenterology, 122: 889–896.PubMedGoogle Scholar
  47. Forns, X., Ampurdanes, S., Sanchez-Tapias, J.M., Guilera, M., Sans, M., Sanchez-Fueyo, A., Quinto, L., Joya, P., Bruguera, M., Rodes, J. (2001). Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. Journal of Hepatology, 35: 265–271.PubMedGoogle Scholar
  48. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). PEGinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347: 975–982.PubMedGoogle Scholar
  49. Gane, E.J., Lo, S.K., Riordan, S.M., Portmann, B.C., Lau, J.Y., Naoumov, N.V., Williams, R. (1998). A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation. Hepatology, 27: 1403–1407.PubMedGoogle Scholar
  50. Gane, E.J., Naoumov, N.V., Qian, K.P., Mondelli, M.U., Maertens, G., Portmann, B.C., Lau, J.Y., Williams, R. (1996). A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology, 110: 167–177.PubMedGoogle Scholar
  51. Garcia-Retortillo, M., Forns, X., Feliu, A., Moitinho, E., Costa, J., Navasa, M., Rimola, A., Rodes, J. (2002). Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology, 35: 680–687.PubMedGoogle Scholar
  52. Ghobrial, R.M., Farmer, D.G., Baquerizo, A., Colquhoun, S., Rosen, H.R., Yersiz, H., Markmann, J.F., Drazan, K.E., Holt, C., Imagawa, D., Goldstein, L.I., Martin, P., Busuttil, R.W. (1999). Orthotropic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Annals of Surgery, 229: 824–831; discussion 831–823.PubMedGoogle Scholar
  53. Giostra, E., Kullak-Ublick, G.A., Keller, W., Fried, R., Vanlemmens, C., Kraehenbuhl,S., Locher, S., Egger, H.P., Clavien, P.A., Hadengue, A., Mentha, G., Morel, P., Negro, F. (2004). Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transplant International, 17: 169–176.PubMedGoogle Scholar
  54. Gordon, A., Mitchell, J.L., Morales, B.M., Thomson, K., Pedersen J.S., McLean, C., Angus, P.W., Roberts, S.K. (2005). Sustained virological response is associated with reduction of HVPG in chronic hepatitis C related cirrhosis. Journal of Hepatology, 42: 205A.Google Scholar
  55. Gordon, S.C., Bayati, N., Silverman, A.L. (1998). Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology, 28: 562–567.PubMedGoogle Scholar
  56. Gramenzi, A., Andreone, P., Fiorino, S., Camma, C., Giunta, M., Magalotti, D., Cursaro, C., Calabrese, C., Arienti, V., Rossi, C., Di Febo, G., Zoli, M., Craxi, A., Gasbarrini, G., Bernardi, M. (2001). Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut, 48: 843–848.PubMedGoogle Scholar
  57. Guerrero, R.B., Batts, K.P., Burgart, L.J., Barrett, S.L., Germer, J.J., Poterucha, J.J., Wiesner, R.H., Charlton, M.R., Persing, D.H. (2000). Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Modern Pathology, 13: 229–237.PubMedGoogle Scholar
  58. Hadziyannis, S.J., Sette, H., Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M. (2004). PEGinterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.PubMedGoogle Scholar
  59. Heathcote, J., Main, J. (2005). Treatment of hepatitis C. Journal of Viral Hepatitis, 12: 223–235.PubMedGoogle Scholar
  60. Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., De Pamphilis, J. (2000). PEGinterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. New England Juornal of Medicine, 343: 1673–1680.Google Scholar
  61. Jain, A., Demetris, A.J., Manez, R., Tsamanadas, A.C., Van Thiel, D., Rakela, J., Starzl, T.E., Fung, J.J. (1998). Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transplantation and Surgery, 4: 197–203.PubMedGoogle Scholar
  62. Janssen, H.L., Brouwer, J.T., Nevens, F., Sanchez-Tapias, J.M., Craxi, A., Hadziyannis, S. (1993). Fatal hepatic decompensation associated with interferon alpha. European concerted action on viral hepatitis (Eurohep). British Medical Journal, 306: 107–108.PubMedGoogle Scholar
  63. Jen, J.F., Glue, P., Gupta, S., Zambas, D., Hajian, G. (2000). Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Therapeutic Drug Monitoring, 22: 555–565.PubMedGoogle Scholar
  64. Kerkar, N., Hadzic, N., Davies, E.T., Portmann, B., Donaldson, P.T., Rela, M., Heaton, N.D., Vergani, D., Mieli-Vergani, G. (1998). De-novo autoimmune hepatitis after liver transplantation. Lancet, 351: 409–413.PubMedGoogle Scholar
  65. Kim, W.R. (2002). The burden of hepatitis C in the United States. Hepatology, 36 (5 Suppl. 1): S30–34.PubMedGoogle Scholar
  66. Kowdley, K.V. (2005). Hematologic side effects of interferon and ribavirin therapy. Jouranl of Clinical Gastroenterology, 39 (1 Suppl.): S3–8.Google Scholar
  67. Kugelmas, M., Osgood, M.J., Trotter, J.F., Bak, T., Wachs, M., Forman, L., Kam, I., Everson, G.T. (2003). Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transplantation, 9: 1159–1165.PubMedGoogle Scholar
  68. Lake, J.R., Shorr, J.S., Steffen, B.J., Chu, A.H., Gordon, R.D., Wiesner, R.H. (2005). Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. American Journal of Transplantation, 5: 549–557.PubMedGoogle Scholar
  69. Lee, S.S., Bain, V.G., Peltekian, K., Krajden, M., Yoshida, E.M., Deschenes, M., Heathcote, J., Bailey, R.J., Simonyi, S., Sherman, M. (2006). Treating chronic hepatitis C with PEGylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Alimentary Pharmacology & Therapeutics, 23: 397–408.Google Scholar
  70. Lee, W.M., Dienstag, J.L., Lindsay, K.L., Lok, A.S., Bonkovsky, H.L., Shiffman, M.L., Everson, G.T., Di Bisceglie, A.M., Morgan, T.R., Ghany, M.G., Morishima, C., Wright, E.C., Everhart, J.E. (2004). Evolution of the HALT-C trial: PEGylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials, 25: 472–492.PubMedGoogle Scholar
  71. Licata, A., Di Bona, D., Schepis, F., Shahied, L., Craxi, A., Camma, C. (2003). When and how to treat acute hepatitis C? Journal of Hepatology, 39: 1056–1062.PubMedGoogle Scholar
  72. Llovet, J.M., Burroughs, A., Bruix, J. (2003). Hepatocellular carcinoma. Lancet, 362: 1907–1917.PubMedGoogle Scholar
  73. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001). PEGinterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.PubMedGoogle Scholar
  74. Manns, M.P., Wedemeyer, H., Cornberg, M. (2006). Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 55: 1350–1359.PubMedGoogle Scholar
  75. Marcos, A., Eghtesad, B., Fung, J.J., Fontes, P., Patel, K., Devera, M., Marsh, W., Gayowski, T., Demetris, A.J., Gray, E.A., Flynn, B., Zeevi, A., Murase, N., Starzl, T.E. (2004). Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation, 78: 966–971.PubMedGoogle Scholar
  76. Marrache, F., Consigny, Y., Ripault, M.P., Cazals-Hatem, D., Martinot, M., Boyer, N., Degott, C., Valla, D., Marcellin, P. (2005). Safety and efficacy of PEGinterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. Journal of Viral Hepatitis, 12: 421–428.PubMedGoogle Scholar
  77. Mazzella, G., Accogli, E., Sottili, S., Festi, D., Orsini, M., Salzetta, A., Novelli, V., Cipolla, A., Fabbri, C., Pezzoli, A., Roda, E. (1996). Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. Juornal of Hepatology, 24: 141–147.Google Scholar
  78. Mazziotti, G., Sorvillo, F., Morisco, F., Carbone, A., Rotondi, M., Stornaiuolo, G., Precone, D.F., Cioffi, M., Gaeta, G.B., Caporaso, N., Carella, C. (2002). Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer, 95: 2539–2545.PubMedGoogle Scholar
  79. McCaughan, G.W., Zekry, A. (2002). Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transplantation, 8 (10 Suppl. 1): S7–S13.PubMedGoogle Scholar
  80. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. (1998). Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339: 1485–1492.PubMedGoogle Scholar
  81. Mukherjee, S. (2005). PEGylated interferon alpha-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplantation Proceedings, 37: 4403–4405.PubMedGoogle Scholar
  82. Nakagawa, M., Sakamoto, N., Enomoto, N., Tanabe, Y., Kanazawa, N., Koyama, T., Kurosaki, M., Maekawa, S., Yamashiro, T., Chen, C.H., Itsui, Y., Kakinuma, S., Watanabe, M. (2004). Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochemical and Biophysical Research Communications, 313: 42–47.PubMedGoogle Scholar
  83. Nakagawa, M., Sakamoto, N., Tanabe, Y., Koyama, T., Itsui, Y., Takeda, Y., Chen, C.H., Kakinuma, S., Oooka, S., Maekawa, S., Enomoto, N., Watanabe, M. (2005). Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology, 129: 1031–1041.PubMedGoogle Scholar
  84. Neff, G.W., Montalbano, M., O’Brien, C.B., Nishida, S., Safdar, K., Bejarano, P.A., Khaled, A.S., Ruiz, P., Slapak-Green, G., Lee, M., Nery, J., De Medina, M., Tzakis, A., Schiff, E.R. (2004). Treatment of established recurrent hepatitis C in liver-transplant recipients with PEGylated interferon-alpha-2b and ribavirin therapy. Transplantation, 78: 1303–1307.PubMedGoogle Scholar
  85. Neumann, U.P., Berg, T., Bahra, M., Seehofer, D., Langrehr, J.M., Neuhaus, R., Radke, C., Neuhaus, P. (2004). Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. Journal of Hepatology, 41: 830–836.PubMedGoogle Scholar
  86. Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C.M., Mohr, L., Haussinger, D. (1996). Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. New England Journal of Medicine, 334: 1422–1427.PubMedGoogle Scholar
  87. Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., Haussinger, D. (1998). Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 28: 1687–1695.PubMedGoogle Scholar
  88. NIH Consensus Statement on Management of Hepatitis C: 2002. (2002). NIH Consensus and State of the Science Statements, 19: 1–46.Google Scholar
  89. Papatheodoridis, G.V., Manesis, E., Hadziyannis, S.J. (2001). The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. Journal of Hepatology, 34: 306–313.PubMedGoogle Scholar
  90. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. International Journal of Cancer, 94: 153–156.Google Scholar
  91. Pelletier, S.J., Raymond, D.P., Crabtree, T.D., Berg, C.L., Iezzoni, J.C., Hahn, Y.S., Sawyer, R.G., Pruett, T.L. (2000). Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology, 32: 418–426.PubMedGoogle Scholar
  92. Pelletier, S.J., Raymond, D.P., Crabtree, T.D., Iezzoni, J.C., Sawyer, R.G., Hahn, Y.S., Pruett, T.L. (2000). Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation. Hepatology, 32: 375–381.PubMedGoogle Scholar
  93. Planas, R., Balleste, B., Alvarez, M.A., Rivera, M., Montoliu, S., Galeras, J.A., Santos, J., Coll, S., Morillas, R.M., Sola, R. (2004). Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology, 40: 823–830.PubMedGoogle Scholar
  94. Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M.H., Albrecht, J. (2002). Impact of PEGylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 122: 1303–1313.PubMedGoogle Scholar
  95. Poynard, T., Schiff, E., Terg, R., Goncales, F., Diago, M., Reichen, J., Moreno, R, Bedossa, P., Burroughs, M., Albrecht, J. (2005). Sustained virologic response (SVR) in EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD). Journal of Hepatology, 42: 40A.Google Scholar
  96. Prieto, M., Berenguer, M., Rayon, J.M., Cordoba, J., Arguello, L., Carrasco, D., Garcia-Herola, A., Olaso, V., De Juan, M., Gobernado, M., Mir, J., Berenguer, J. (1999). High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology, 29: 250–256.PubMedGoogle Scholar
  97. Rifai, K., Sebagh, M., Karam, V., Saliba, F., Azoulay, D., Adam, R., Castaing, D., Bismuth, H., Reynes, M., Samuel, D., Feray, C. (2004). Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. Journal of Hepatology, 41: 446–453.PubMedGoogle Scholar
  98. Rodriguez-Luna, H., Khatib, A., Sharma, P., De Petris, G., Williams, J.W., Ortiz, J., Hansen, K., Mulligan, D., Moss, A., Douglas, D.D., Balan, V., Rakela, J., Vargas, H.E. (2004). Treatment of recurrent hepatitis C infection after liver transplantation with combination of PEGylated interferon alpha2b and ribavirin: an open-label series. Transplantation, 77: 190–194.PubMedGoogle Scholar
  99. Rosen, H.R., Shackleton, C.R., Higa, L., Gralnek, I.M., Farmer, D.A., McDiarmid, S.V., Holt, C., Lewin, K.J., Busuttil, R.W., Martin, P. (1997). Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. American Journal of Gastroenterology, 92: 1453–1457.PubMedGoogle Scholar
  100. Saito, Y., Saito, H., Tada, S., Nakamoto, N., Horikawa, H., Kurita, S., Kitamura, K., Ebinuma, H., Ishii, H., Hibi, T. (2005). Effect of long-term interferon therapy for refractory chronic hepatitis C: preventive effect on hepatocarcinogenesis. Hepatogastroenterology, 52: 1491–1496.PubMedGoogle Scholar
  101. Salcedo, M., Vaquero, J., Banares, R., Rodriguez-Mahou, M., Alvarez, E., Vicario, J.L., Hernandez-Albujar, A., Tiscar, J.L., Rincon, D., Alonso, S., De Diego, A., Clemente, G. (2002). Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology, 35: 349–356.PubMedGoogle Scholar
  102. Samuel, C.E. (2001). Antiviral actions of interferons. Clinical Microbiology Reviews, 14: 778–809, table of contents.PubMedGoogle Scholar
  103. Samuel, D., Bizollon, T., Feray, C., Roche, B., Ahmed, S.N., Lemonnier, C., Cohard, M., Reynes, M., Chevallier, M., Ducerf, C., Baulieux, J., Geffner, M., Albrecht, J.K., Bismuth, H., Trepo, C. (2003). Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology, 124: 642–650.PubMedGoogle Scholar
  104. Samuel, D., Forns, X., Berenguer, M., Trautwein, C., Burroughs, A., Rizzetto, M., Trepo, C. (2006). Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). Journal of Hepatology, 45: 127–143.PubMedGoogle Scholar
  105. Sanchez-Fueyo, A., Restrepo, J.C., Quinto, L., Bruguera, M., Grande, L., Sanchez-Tapias, J.M., Rodes, J., Rimola, A. (2002). Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation, 73: 56–63.PubMedGoogle Scholar
  106. Serfaty, L., Aumaitre, H., Chazouilleres, O., Bonnand, A.M., Rosmorduc, O., Poupon, R.E., Poupon, R. (1998). Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 27: 1435–1440.PubMedGoogle Scholar
  107. Sheiner, P.A., Schwartz, M.E., Mor, E., Schluger, L.K., Theise, N., Kishikawa, K., Kolesnikov, V., Bodenheimer, H., Emre, S., Miller, C.M. (1995). Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotropic liver transplantation. Hepatology, 21: 30–34.PubMedGoogle Scholar
  108. Shergill, A.K., Khalili, M., Straley, S., Bollinger, K., Roberts, J.P., Ascher, N.A., Terrault, N.A. (2005). Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. American Journal of Transplantation, 5: 118–124.PubMedGoogle Scholar
  109. Shiffman, M.L., Hofmann, C.M., Thompson, E.B., Ferreira-Gonzalez, A., Contos, M.J., Koshy, A., Luketic, V.A., Sanyal, A.J., Mills, A.S., Garrett, C.T. (1997). Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology, 26: 780–785.PubMedGoogle Scholar
  110. Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., Arakawa, Y., Hashimoto, E., Hirota, K., Yoshida, H., Ohashi, Y., Omata, M. (2005). Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Annals of Internal Medicine, 142: 105–114.PubMedGoogle Scholar
  111. Singh, N., Gayowski, T., Wannstedt, C.F., Shakil, A.O., Wagener, M.M., Fung, J.J., Marino, I.R. (1998). Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation, 65: 82–86.PubMedGoogle Scholar
  112. Stravitz, R.T., Shiffman, M.L., Sanyal, A.J., Luketic, V.A., Sterling, R.K., Heuman, D.M., Ashworth, A., Mills, A.S., Contos, M., Cotterell, A.H., Maluf, D., Posner, M.P., Fisher, R.A. (2004). Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transplantation, 10: 850–858.PubMedGoogle Scholar
  113. Sugawara, Y., Makuuchi, M., Matsui, Y., Kishi, Y., Akamatsu, N., Kaneko, J., Kokudo, N. (2004). Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation, 78: 1308–1311.PubMedGoogle Scholar
  114. Terrault, N.A. (2005). Treatment of recurrent hepatitis C in liver transplant recipients. Clinical Gastroenterology and Hepatology, 3 (10 Suppl. 2): S125–131.PubMedGoogle Scholar
  115. Thomas, R.M., Brems, J.J., Guzman-Hartman, G., Yong, S., Cavaliere, P., Van Thiel, D.H. (2003). Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transplantation, 9: 905–915.PubMedGoogle Scholar
  116. Tong, M.J., el-Farra, N.S., Reikes, A.R., Co, R.L. (1995). Clinical outcomes after transfusion-associated hepatitis C. New England Journal of Medicine, 332: 1463–1466.PubMedGoogle Scholar
  117. Toniutto, P., Fabris, C., Fumo, E., Apollonio, L., Caldato, M., Avellini, C., Minisini, R., Pirisi, M. (2005). PEGylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. Journal of Gastroenterology and Hepatology, 20: 577–582.PubMedGoogle Scholar
  118. Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993). Risk factors for hepatocellular carcinoma among patients with chronic liver disease. New England Journal of Medicine, 328: 1797–1801.PubMedGoogle Scholar
  119. Valla, D.C., Chevallier, M., Marcellin, P., Payen, J.L., Trepo, C., Fonck, M., Bourliere, M., Boucher, E., Miguet, J.P., Parlier, D., Lemonnier, C., Opolon, P. (1999). Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology, 29: 1870–1875.PubMedGoogle Scholar
  120. Velazquez, R.F., Rodriguez, M., Navascues, C.A., Linares, A., Perez, R., Sotorrios, N.G., Martinez, I., Rodrigo, L. (2003). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 37: 520–527.PubMedGoogle Scholar
  121. Wang, C.S., Ko, H.H., Yoshida, E.M., Marra, C.A., Richardson, K. (2006). Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. American Journal of Transplantation, 6: 1586–1599.PubMedGoogle Scholar
  122. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., Shimotohno, K. (2003). Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 38: 1282–1288.PubMedGoogle Scholar
  123. WHO (1999). World Health Organization. Weekly Epidemiological Record, pp. 421–428.Google Scholar
  124. Wiesner, R.H., Sorrell, M., Villamil, F. (2003). Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplantation, 9: S1–9.PubMedGoogle Scholar
  125. Wilson, L.E., Widman, D., Dikman, S.H., Gorevic, P.D. (2002). Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Seminars in Arthritis and Rheumatism, 32: 163–173.PubMedGoogle Scholar
  126. Wright, T.L., Combs, C., Kim, M., Ferrell, L., Bacchetti, P., Ascher, N., Roberts, J., Wilber, J., Sheridan, P., Urdea, M. (1994). Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology, 20 (4 Pt. 1): 773–779.PubMedGoogle Scholar
  127. Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Lefkowitch, J.H., Ludwig, J., Okuda, K. (1996). The long-term pathological evolution of chronic hepatitis C. Hepatology, 23: 1334–1340.PubMedGoogle Scholar
  128. Yedibela, S., Schuppan, D., Muller, V., Schellerer, V., Tannapfel, A., Hohenberger, W., Meyer, T. (2005). Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver International, 25: 717–722.PubMedGoogle Scholar
  129. Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S., Yamada, G., Omata, M. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Annals of Internal Medicine, 131:174–181.PubMedGoogle Scholar
  130. Yoshida, H., Tateishi, R., Arakawa, Y., Sata, M., Fujiyama, S., Nishiguchi, S., Ishibashi, H., Yamada, G., Yokosuka, O., Shiratori, Y., Omata, M. (2004). Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut, 53: 425–430.PubMedGoogle Scholar
  131. Zeuzem, S., Schmidt, J.M., Lee, J.H., Ruster, B., Roth, W.K. (1996). Effect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology, 23: 366–371.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Davide Festi
    • 1
  • Francesca Lodato
  • Giuseppe Mazzella
  • Antonio Colecchia
  1. 1.Dipartimento diMedicina Interna e GastroenterologiaPoliclinico S.Orsola-MalpighiVia Massarenti 9Italy

Personalised recommendations